SynBiotic Inkomsten in het verleden
Verleden criteriumcontroles 0/6
SynBiotic's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 30.6% per year.
Belangrijke informatie
-48.7%
Groei van de winst
-37.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 30.6% |
| Rendement op eigen vermogen | -76.6% |
| Nettomarge | -275.3% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe SynBiotic geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -11 | 3 | 0 |
| 31 Dec 22 | 8 | -24 | 6 | 0 |
| 31 Dec 21 | 9 | -13 | 2 | 0 |
| 31 Dec 20 | 5 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: SBX is currently unprofitable.
Groeiende winstmarge: SBX is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SBX is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Versnelling van de groei: Unable to compare SBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SBX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Rendement op eigen vermogen
Hoge ROE: SBX has a negative Return on Equity (-76.57%), as it is currently unprofitable.